Copyright
©The Author(s) 2022.
World J Transplant. Nov 18, 2022; 12(11): 365-377
Published online Nov 18, 2022. doi: 10.5500/wjt.v12.i11.365
Published online Nov 18, 2022. doi: 10.5500/wjt.v12.i11.365
Table 1 Study participants’ age, sex, and primary cause of end-stage liver disease
No. | Age | Sex | Primary cause |
1 | 32 | Female | Primary biliary cholangitis |
2 | 53 | Female | Liver hemangioma |
3 | 38 | Female | Liver hemangioma |
4 | 53 | Male | Hepatitis B virus |
5 | 38 | Male | Autoimmune hepatitis |
6 | 51 | Female | Hepatocellular carcinoma |
7 | 32 | Male | Hepatocellular carcinoma |
8 | 61 | Female | Hepatitis B virus |
9 | 63 | Male | Non-alcoholic fatty liver disease |
10 | 47 | Female | Hepatic cystadenomas |
11 | 62 | Female | Primary biliary cholangitis |
12 | 54 | Male | Hepatitis C virus |
13 | 52 | Male | Alcohol-related liver disease |
14 | 63 | Male | Alcohol-related liver disease |
15 | 49 | Female | Hepatitis B virus |
16 | 52 | Male | Hepatitis B virus |
17 | 50 | Male | Hepatitis B virus |
18 | 52 | Female | Non-alcoholic fatty liver disease |
19 | 50 | Male | Non-alcoholic fatty liver disease |
20 | 50 | Female | Primary biliary cholangitis |
Table 2 International Physical Activity Questionnaire responses
No. | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Result |
1 | 0 d | - | 2 d | 0 h 15 min | 5 d | 1 h 0 min | 8 h 0 min | Moderate |
2 | 2 d | 0 h 15 min | 4 d | 30 min | 5 d | 1 h 0 min | 4 h 30 min | Moderate |
3 | 0 d | - | 2 d | 0 h 20 min | 7 d | 1 h 30 min | 6 h 0 min | Moderate |
4 | 0 d | - | 0 d | - | 3 d | 0 h 30 min | 8 h 0 min | Low |
5 | 0 d | - | 3 d | 0 h 30 min | 3 d | 1 h 0 min | 6 h 0 min | Moderate |
6 | 0 d | - | 2 d | 0 h 20 min | 4 d | 0 h 45 min | 6 h 30 min | Moderate |
7 | 0 d | - | 3 d | 0 h 45 min | 4 d | 1 h 15 min | 4 h 30 min | Moderate |
8 | 0 d | - | 2 d | 0 h 15 min | 2 d | 0 h 30 min | 7 h 30 min | Low |
9 | 0 d | - | 0 d | - | 3 d | 0 h 15 min | 9 h 30 min | Low |
10 | 0 d | - | 3 d | 0 h 30 min | 3 d | 0 h 45 min | 6 h 15 min | Moderate |
11 | 0 d | - | 0 d | - | 3 d | 0 h 15 min | 9 h 15 min | Low |
12 | 0 d | - | 2 d | 0 h 20 min | 3 d | 0 h 30 min | 6 h 45 min | Low |
13 | 0 d | - | 2 d | 0 h 15 min | 4 d | 0 h 20 min | 7 h 0 min | Low |
14 | 0 d | - | 0 d | - | 5 d | 0 h 15 min | 8 h 0 min | Low |
15 | 0 d | - | 0 d | - | 3 d | 0 h 40 min | 7 h 30 min | Low |
16 | 0 d | - | 2 d | 0 h 20 min | 3 d | 0 h 30 min | 6 h 0 min | Low |
17 | 0 d | - | 3 d | 0 h 30 min | 4 d | 1 h 30 min | 4 h 0 min | Moderate |
18 | 0 d | - | 3 d | 0 h 20 min | 4 d | 1 h 0 min | 6 h 0 min | Moderate |
19 | 0 d | - | 0 d | - | 7 d | 1 h 15 min | 5 h 30 min | Moderate |
20 | 0 d | - | 0 d | - | 3 d | 0 h 30 min | 8 h 0 min | Low |
Table 3 Peak oxygen uptake and anaerobic threshold results
No. | Group | VO2peak in mL/kg/min | AT in mL/kg/min |
1 | Active | 29.9 | 15.8 |
2 | Active | 40.8 | 21.1 |
3 | Active | 27.1 | 18.0 |
4 | Sedentary | 18.9 | 14.8 |
5 | Active | 25.7 | 14.1 |
6 | Active | 24.2 | 15.0 |
7 | Active | 39.6 | 18.8 |
8 | Sedentary | 18.4 | 14.2 |
9 | Sedentary | 13.8 | 12.8 |
10 | Active | 22.2 | 14.2 |
11 | Sedentary | 13.2 | 11.6 |
12 | Sedentary | 25.3 | 17.0 |
13 | Sedentary | 20.0 | 14.7 |
14 | Sedentary | 16.9 | 12.8 |
15 | Sedentary | 17.0 | 13.8 |
16 | Sedentary | 19.5 | 14.0 |
17 | Active | 30.0 | 16.9 |
18 | Active | 28.5 | 16.5 |
19 | Active | 29.8 | 16.7 |
20 | Sedentary | 18.1 | 13.9 |
Table 4 Six-minute walking test results
No. | Group | 6-min walking test in m |
1 | Active | 396 |
2 | Active | 456 |
3 | Active | 595 |
4 | Sedentary | 250 |
5 | Active | 433 |
6 | Active | 397 |
7 | Active | 429 |
8 | Sedentary | 347 |
9 | Sedentary | 264 |
10 | Active | 502 |
11 | Sedentary | 259 |
12 | Sedentary | 360 |
13 | Sedentary | 431 |
14 | Sedentary | 362 |
15 | Sedentary | 320 |
16 | Sedentary | 330 |
17 | Active | 460 |
18 | Active | 456 |
19 | Active | 458 |
20 | Sedentary | 324 |
Table 5 Liver Frailty Index test results
No. | Hand grip strength in kg | Sit-to-stand in s | Balance test in s | LFI | ||||
Att. 1 | Att. 2 | Att. 3 | Side-by-side | Semi-tandem | Tandem | |||
1 | 18 | 19 | 19 | 12.4 | 10.0 | 10.0 | 10.0 | 3.95 |
2 | 26 | 26 | 25 | 8.5 | 10.0 | 10.0 | 10.0 | 3.11 |
3 | 25 | 24 | 24 | 10.1 | 10.0 | 10.0 | 10.0 | 3.42 |
4 | 19 | 18 | 18 | 16.8 | 7.9 | 9.1 | 8.2 | 4.76 |
5 | 26 | 27 | 27 | 11.0 | 10.0 | 10.0 | 10.0 | 3.9 |
6 | 19 | 18 | 19 | 13.1 | 9.1 | 10.0 | 8.9 | 4.08 |
7 | 30 | 28 | 29 | 10.0 | 10.0 | 10.0 | 10.0 | 3.71 |
8 | 14 | 14 | 13 | 17.2 | 8.5 | 9.2 | 8.1 | 4.66 |
9 | 13 | 14 | 14 | 17.6 | 8.5 | 9.4 | 8.0 | 4.92 |
10 | 18 | 17 | 18 | 13.3 | 9.0 | 10.0 | 9.0 | 4.15 |
11 | 12 | 11 | 12 | 16.1 | 9.3 | 10.0 | 9.0 | 4.62 |
12 | 20 | 19 | 19 | 11.9 | 10.0 | 10.0 | 10.0 | 4.23 |
13 | 26 | 27 | 28 | 12.2 | 10.0 | 10.0 | 10.0 | 4.00 |
14 | 22 | 21 | 21 | 11.8 | 10.0 | 10.0 | 10.0 | 4.15 |
15 | 18 | 18 | 17 | 12.8 | 10.0 | 10.0 | 10.0 | 4.03 |
16 | 18 | 19 | 18 | 13.0 | 9.5 | 9.8 | 8.9 | 4.42 |
17 | 27 | 27 | 26 | 9.4 | 10.0 | 10.0 | 10.0 | 3.70 |
18 | 19 | 20 | 20 | 11.3 | 10.0 | 10.0 | 10.0 | 3.80 |
19 | 27 | 28 | 27 | 9.8 | 10.0 | 10.0 | 10.0 | 3.74 |
20 | 15 | 14 | 14 | 14.2 | 9.0 | 9.4 | 8.4 | 4.43 |
Table 6 Mean values of peak oxygen uptake, anaerobic threshold, 6-min walking test and, Liver Frailty Index
Table 7 Correlation analysis between activity level and model for end-stage liver disease score peak oxygen uptake, anaerobic threshold, 6-min walking test, and Liver Frailty Index
Value | rpb | P value |
MELD | -0.212 | > 0.05 |
VO2peak in mL/kg/min | 0.781 | < 0.001 |
AT in mL/kg/min | 0.618 | < 0.01 |
6MWT in m | 0.779 | < 0.001 |
LFI | -0.747 | < 0.001 |
- Citation: Oikonomou IM, Sinakos E, Antoniadis N, Goulis I, Giouleme O, Anifanti M, Katsanos G, Karakasi KE, Tsoulfas G, Kouidi E. Effects of an active lifestyle on the physical frailty of liver transplant candidates. World J Transplant 2022; 12(11): 365-377
- URL: https://www.wjgnet.com/2220-3230/full/v12/i11/365.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i11.365